Eagle Genomics expands stateside with new JLABS digs in Manhattan

Eagle Genomics debuted its new space with a panel discussion. From left to right: Anthony Finbow, CEO of Eagle Genomics; Rob Genieser, managing partner of ETF Partners; David Houlding, principal healthcare lead, Industry Experiences, Cloud + AI at Microsoft; Sam Samaras, global vice president science and technology, beauty and personal care R&D at Unilever, and Dirk Gevers, global head of microbiome solutions at Janssen's World Without Disease Accelerator. (Eagle Genomics)

U.K.-based Eagle Genomics has expanded across the pond to a new office in New York. The company will take up a spot at the JLABS incubator located at the New York Genome Center. 

Eagle Genomics’ AI-augmented knowledge discovery platform, dubbed the e[automateddatascientist], is designed to cut the time and cost of research, by “unraveling the connections” within life sciences data. The conversational learning software platform can crunch the complexity and scale of genomics and microbiomics data, the company said in a statement on Tuesday. 

The idea is to speed up the analysis of data, boosting productivity and ultimately shortening the time it takes to arrive at a product. 

The company already had offices in Paris and London, as well as in its native Cambridge. With the launch of the New York location, “Eagle Genomics solidifies its presence in the US and positions itself at the emerging center of international genomics innovation, where deep tech meets deep science,” the company said in the statement.

RELATED: Microsoft turns to the microbiome with Eagle Genomics partnership

"We are delighted to be expanding our presence in the US and to be joining the innovative community at JLABS," said Eagle Genomics CEO Anthony Finbow, in the statement. "Having a home at the heart of genomics research in New York, close to many of our customers, will provide an even deeper understanding of the challenges they face and enable the platform to be deployed to assist in pushing the boundaries of scientific research and addressing the grand challenges of our age." 

Eagle Genomics officially debuted the New York office last Thursday, with a discussion panel asking the question, “Will the microbiome revolution happen?” Top microbiome researcher Dirk Gevers, global head of microbiome solutions at Janssen’s World Without Disease Accelerator, weighed in, alongside colleagues from Unilever, ETF Partners and Microsoft.

Suggested Articles

Biopharma cancer drug developer Cassandra Matney, M.D., has joined CRO Premier Research as its new senior medical director.

As the pandemic rages on and clinical trials are becoming increasingly siteless, eSource trial firm Clinical Ink has become an M&A target.

Pfizer has always been a heavy user of CROs, and over the past few months it’s been ramping up its partnerships.